Citius Oncology Inc (CTOR)

Dec 07, 2024

Major Improvements In Citius Oncology Inc (CTOR) Stock Need To Be Considered - Stocks Register

Dec 07, 2024

Dec 06, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online

Dec 06, 2024

Dec 03, 2024

“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside To Watch” - Barchart

Dec 03, 2024

Dec 01, 2024

Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR) - Defense World

Dec 01, 2024

Nov 29, 2024

Loss-Making Citius Oncology, Inc. (NASDAQ:CTOR) Expected To Breakeven In The Medium-Term - Simply Wall St

Nov 29, 2024

Nov 28, 2024

Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - Yahoo Finance

Nov 28, 2024

Nov 26, 2024

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com

Nov 26, 2024

Nov 26, 2024

Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com

Nov 26, 2024

Nov 25, 2024

Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results | CTXR Stock News - StockTitan

Nov 25, 2024

Nov 23, 2024

CTOR stock touches 52-week low at $0.9 amid market challenges - Investing.com Canada

Nov 23, 2024

Nov 22, 2024

CTOR stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 22, 2024

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan

Nov 22, 2024

Nov 20, 2024

Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN

Nov 20, 2024

Nov 19, 2024

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace

Nov 19, 2024

Nov 18, 2024

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - BioSpace

Nov 18, 2024

Nov 18, 2024

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan

Nov 15, 2024

Nov 11, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - BioSpace

Nov 11, 2024

Nov 11, 2024

Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma

Nov 11, 2024

Oct 10, 2024

CTOR stock touches 52-week low at $1.02 amid market challenges - Investing.com India

Oct 10, 2024

Oct 09, 2024

CTOR stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa

Oct 09, 2024

Oct 02, 2024

CTOR stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa

Oct 02, 2024

Oct 01, 2024

CTOR stock touches 52-week low at $1.29 amid market challenges - Investing.com

Oct 01, 2024

Oct 01, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com

Oct 01, 2024

Sep 27, 2024

Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga

Sep 27, 2024

Sep 24, 2024

CTMX stock rated an Overweight by Piper Sandler - Knox Daily

Sep 24, 2024

Sep 24, 2024

CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Sep 24, 2024

Sep 24, 2024

Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex

Sep 24, 2024

Sep 24, 2024

Cytek BioSciences Inc (CTKB)’s stock performance: a year in review - US Post News

Sep 24, 2024

Sep 24, 2024

Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 24, 2024

Sep 23, 2024

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Sep 23, 2024

Sep 23, 2024

Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's

Sep 23, 2024

Sep 23, 2024

Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex

Sep 23, 2024

Sep 21, 2024

XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World

Sep 21, 2024

Sep 20, 2024

CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada

Sep 20, 2024

Sep 17, 2024

CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle

Sep 17, 2024

Sep 13, 2024

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Sep 13, 2024

Sep 11, 2024

Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com

Sep 11, 2024

Sep 06, 2024

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive

Sep 06, 2024

Sep 05, 2024

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald

Sep 05, 2024

Sep 05, 2024

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow

Sep 05, 2024

Sep 02, 2024

A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News

Sep 02, 2024

Sep 02, 2024

Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex

Sep 02, 2024

Aug 28, 2024

CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com

Aug 28, 2024

Aug 21, 2024

Citius Oncology Inc. (CTOR) requires closer examination - US Post News

Aug 21, 2024

Aug 19, 2024

Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks

Aug 19, 2024

Aug 19, 2024

CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle

Aug 19, 2024